Crane Co (CR) Stock News

Carpenter Technology (CRS) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company is expected to earn $13.28 per share for fiscal year 2027, with analysts raising consensus estimates by 7.2% over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential near-term price appreciation.

Oscar Health (OSCR) gained 1.76% to $32.91, outperforming a declining market. The company holds a Zacks Rank #1 (Strong Buy) with consensus EPS estimates up 79.25% year-over-year and revenue projected at $4.72 billion (+58.14% YoY). Full-year earnings are expected at $1.83 per share (+208.28%) with revenue of $18.81 billion (+60.77%). Over the last 30 days, EPS estimates have risen 18.79%, though the stock trades at a Forward P/E of 17.64, above its industry average of 9.84.

Crocs (CROX) closed at $120.33, up 1.81%, outperforming the S&P 500's 0.58% gain. The company is expected to report EPS of $3.3 (up 13.01% YoY) with revenue projected at $1 billion. However, Crocs carries a Zacks Rank #4 (Sell) rating despite trading at a Forward P/E of 8.47, below the industry average of 15.12, and a PEG ratio of 0.99.

The Rosen Law Firm is investigating potential securities claims against America's Car-Mart, Inc. (NASDAQ: CRMT) for allegedly issuing materially misleading business information. The company reported a first-quarter loss of 69 cents per share compared to 15 cents per share in the prior year, causing the stock to plunge 18.2% on September 4, 2025. Investors who suffered losses are encouraged to join a prospective class action lawsuit.

The global animal model market is projected to grow from USD 2.02 billion in 2025 to USD 3.31 billion by 2034, expanding at a CAGR of 5.46%. Growth is driven by rising pharmaceutical research, CRISPR-Cas9 advances, personalized medicine demand, and vaccine R&D expansion. Rodents remain the dominant animal type, while key players include Charles River Laboratories, Eurofins Scientific, and The Jackson Laboratory.

Smith+Nephew announced the commercial availability of its CARTIHEAL AGILI-C cartilage repair implant in Europe, following its 2024 US launch. The aragonite-based implant demonstrated clinical superiority over standard care in a multicenter randomized controlled trial, showing superior pain relief and functional gains over 5 years. The product will initially be available in 12 European countries.

Smith+Nephew announced the commercial launch of CARTIHEAL AGILI-C, an innovative cartilage repair implant, across Europe. The aragonite-based scaffold will be presented at the ICRS Summit in Portugal (October 8-10). A randomized controlled trial published in the American Journal of Sports Medicine demonstrated clinical superiority over standard surgical care, with patients showing improved pain relief and functional outcomes over 5 years. The implant will initially be available in 8 European countries with plans for further expansion.

Crescent Energy (CRGY) closed at $13.56, up 1.27% on the day but down 2.76% over the past month. The oil and gas company is projected to report strong earnings growth of 42.86% EPS and 32.46% revenue increase year-over-year. With a Zacks Rank of #3 (Hold) and a Forward P/E of 4.83 trading below the industry average of 17.21, the stock appears undervalued. Analyst estimates have increased 24.63% over the past month, indicating growing optimism.

CrowdStrike has been trending with a 26.7% return over the past month, outperforming the S&P 500. While the company shows strong revenue growth (+24.6% current year) and has beaten earnings estimates consistently, Zacks assigns it a Rank #4 (Sell) rating due to negative earnings estimate revisions over the past 30 days (-50% for current quarter, -15% for current year). The stock is also graded F on valuation metrics, indicating it trades at a premium to peers.

Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether MISTRAS Group's $20.35/share sale to H.I.G. Capital, Lifecore Biomedical's $6.28/share sale to Webster Equity Partners, and Marygold Companies' $2.00/share sale to Madison Dearborn Partners represent fair deals for shareholders. The firm may seek increased consideration, additional disclosures, and other relief on behalf of shareholders.

Oscar Health (OSCR) closed at $29.90, down 3.05% in the most recent trading session, underperforming the S&P 500's 0.2% gain. Despite recent monthly gains of 1.68%, the stock faces headwinds from the Finance sector's 4.84% decline. However, analysts project strong earnings growth with EPS expected at -$0.11 (up 79.25% YoY) and revenue of $4.72 billion (up 58.14% YoY). The company holds a Zacks Rank #1 (Strong Buy) rating with a Forward P/E of 16.82, trading at a premium to its industry average of 9.52.

Scor SE (SCRYY) has been upgraded to Zacks Rank #2 (Buy) due to upward trends in earnings estimates. The company is expected to earn $0.49 per share for fiscal year 2026, with analysts raising consensus estimates by 4.3% over the past three months. The upgrade positions Scor in the top 20% of Zacks-covered stocks, suggesting potential near-term stock price appreciation driven by improving business fundamentals.

Charles River Associates (CRAI) shares jumped 12.4% over three months, outperforming its industry. The company reported broad-based revenue growth across all service lines and geographies, with operating income up 19.3% year-over-year. CRAI raised its fiscal 2026 constant-currency revenue guidance to $805-$820 million and returned $31.4 million to shareholders in Q2 through repurchases and dividends.

CRH (building materials company) declined 2.05% in recent trading, underperforming the S&P 500. The stock has fallen 7.31% over the past month. While earnings projections show modest growth (2.71% EPS increase expected), CRH holds a Zacks Rank #4 (Sell) rating. The company trades at a Forward P/E of 14.33, below its industry average, but carries a PEG ratio of 1.66 above the industry average of 1.45.

America's Car-Mart reported a dramatic decline in Q1 FY2027 results, with retail units sold dropping 81.9% and revenue falling 57.3% year-over-year. The poor financial results triggered a stock price decline, prompting a securities law investigation by Holzer & Holzer, LLC into potential federal securities law violations.

Vicor Corporation, a modular power components company, demonstrates strong momentum characteristics with a Zacks Momentum Style Score of A and a Zacks Rank #2 (Buy) rating. The stock has surged 26.6% over the past week and 484.63% over the past year, significantly outperforming the S&P 500. Recent earnings estimate revisions have moved upward, with consensus estimates increasing from $3.12 to $3.65 in the past 60 days, supporting its bullish outlook.

Pomerantz LLP is investigating securities fraud claims against America's Car-Mart (CRMT) following a series of negative disclosures. The company delayed its annual report due to inadequate loan modification disclosures, later restating financial statements. Subsequent earnings reports revealed declining sales volumes (5.7% drop), increased net charge-offs (9.5% vs 6.6%), and a dramatic 57.3% year-over-year revenue decline, causing the stock to plummet from $57.26 to $1.48 per share.

While Wall Street analysts maintain a bullish stance on CrowdStrike with an average brokerage recommendation of 1.69 (Strong Buy), the article cautions investors against relying solely on these recommendations. The Zacks Rank system assigns CrowdStrike a #4 (Sell) rating due to a 67% decline in consensus earnings estimates over the past month, suggesting analysts' growing pessimism about the company's earnings prospects despite positive brokerage recommendations.

The Rosen Law Firm is investigating potential securities claims against America's Car-Mart, Inc. (CRMT) for allegedly issuing materially misleading business information. The company reported a first-quarter loss of 69 cents per share compared to 15 cents per share in the prior year, causing the stock to plunge 18.2% on September 4, 2025. The firm is preparing a class action lawsuit to recover investor losses.

Crescent Energy (CRGY) declined 1.89% to $13.01 in the latest session, underperforming its sector. The company is expected to report strong earnings growth of 60% EPS and 38% revenue growth year-over-year, with full-year projections showing 42.78% earnings growth. However, the stock holds a Zacks Rank #3 (Hold) rating despite trading at a discount with a Forward P/E of 5.17 compared to the industry average of 17.5.

CRH closed at $88.04, up 1.03% in the latest session, but has dropped 9.03% over the past month, underperforming the S&P 500. The company is projected to report earnings of $2.23 per share with modest 0.9% year-over-year growth. CRH holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 14.77, trading at a discount to its industry average. The Building Products sector ranks in the bottom 32% of industries.

Vicor (VICR), a modular power components company, is positioned as a solid investment choice due to remarkably improving earnings outlook and upward analyst estimate revisions. The company carries a Zacks Rank #2 (Buy) rating, with current-quarter earnings expected to grow 38.1% year-over-year and full-year earnings projected at 38.1% growth. The stock has gained 17.9% over the past four weeks, reflecting investor confidence in its earnings prospects.

CoreWeave's stock has declined 53% from its June 2025 peak of $183.58 to $86, but the article argues it may represent a buying opportunity. The AI infrastructure provider operates 51 data centers with over 250,000 Nvidia GPUs, serving major clients like Meta, Microsoft, and OpenAI. Despite explosive 168% revenue growth to $5.1B in 2025 and a $104B contracted revenue backlog, CoreWeave remains unprofitable under GAAP accounting with a concerning 14.3 debt-to-equity ratio. Analysts project continued strong growth through 2028, valuing the stock at just 12x adjusted EBITDA.

Veeva Systems announced that Amgen has selected its Vault CRM platform for global deployment, extending their partnership of over a decade. The deal reinforces Veeva's commercial business momentum, with the company reporting its best CRM quarter ever, 180+ live Vault CRM customers, and confidence in maintaining over 70% market share in life sciences CRM. The global healthcare CRM market is projected to grow at a 6.2% CAGR from 2026 to 2033.

Credo Technology (CRDO) expects fiscal 2027 revenue growth exceeding 85% with expanding optical business becoming a second growth engine alongside its core Active Electrical Cables. However, the stock trades at a significant premium (11.1X forward sales vs. 5.0X sub-industry average) and faces execution risks due to high customer concentration, with the top two customers accounting for 61% of Q1 revenues. The company carries a Zacks Rank #3 (Hold) rating despite strong growth and margin profiles.

Credo Technology (CRDO) has declined 20.3% over the past month despite posting 114.7% year-over-year revenue growth to $479 million in fiscal Q1 2027. The company expects fiscal 2027 revenue growth above 85%, driven by active electrical cables (AECs) and optical products. However, concerns remain regarding high customer concentration (top 2 customers = 61% of revenues), premium valuation at 11.1X forward sales, and rising operating expenses. The stock carries a Zacks Rank #3 (Hold) rating.

Vanguard Consumer Discretionary Index Fund ETF Shares (VCR) received a Zacks ETF Rank of 4 (Sell) rating, making it unsuitable for investors seeking consumer discretionary exposure. The fund has underperformed year-to-date, declining 5.21%, and carries medium risk with a beta of 1.23. Better alternatives include iShares U.S. Home Construction ETF (ITB) and State Street Consumer Discretionary Select Sector SPDR ETF (XLY).

The global rare disease CRO market is projected to grow from $2.07 billion in 2025 to $3.16 billion by 2030, with an 8.9% CAGR. Growth is driven by expanding gene and cell therapy pipelines, increasing orphan drug approvals, precision medicine adoption, and decentralized clinical trials. Key trends include AI integration, patient registries, and real-world evidence utilization.

A comparison of two Medical Services sector stocks, Progyny (PGNY) and Charles River Laboratories (CRL), both with Zacks Rank #2 (Buy). Based on valuation metrics including forward P/E ratio (12.92 vs 24.87), PEG ratio (1.12 vs 2.76), and Value grades (B vs D), Progyny is identified as the superior value opportunity.

Vicor shares surged 17.7% to $216.39 on strong volume, driven by growth in advanced product sales and increased demand for high-efficiency power solutions in AI, industrial, and aerospace markets. The company expects quarterly earnings of $0.75 per share (+19.1% YoY) and revenues of $160 million (+44.9% YoY). However, unchanged earnings estimate revisions over the past 30 days suggest caution about sustained momentum.